Sarepta Therapeutics (SRPT) reported $611.09 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 68.4%. EPS of $2.02 for the same period compares to $0.07 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $529.54 million, representing a surprise of +15.4%. The company delivered an EPS surprise of +81.98%, with the consensus EPS estimate being $1.11.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Sarepta Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Product, net: $513.12 million versus $506.99 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +42.3% change.
- Revenues- PMO Products: $231.27 million versus the seven-analyst average estimate of $228.28 million.
- Revenues- Collaboration: $97.97 million compared to the $21.79 million average estimate based on seven analysts. The reported number represents a change of +4011.1% year over year.
- Revenues- Product, net- ELEVIDYS: $281.85 million versus the seven-analyst average estimate of $277.86 million. The reported number represents a year-over-year change of +131.6%.
View all Key Company Metrics for Sarepta Therapeutics here>>>
Shares of Sarepta Therapeutics have returned -12% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
